Phosphodiesterase inhibitors vs placeboDuration of attacks · primary Raynaud's phenomenon1 finding from 1 reviewVasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 73 participantsLow
Alpha‐blockers vs placeboDuration of attacks · primary Raynaud's phenomenon1 finding from 1 reviewVasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 33 participantsGRADE not reported
Nitrate/nitrate derivatives vs placeboDuration of attacks · primary Raynaud's phenomenon1 finding from 1 reviewVasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 77 participantsGRADE not reported
Selective serotonin reuptake inhibitors vs placeboDuration of attacks per day (minutes) · primary Raynaud's phenomenon1 finding from 1 reviewVasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 41 participantsVery low
Selective serotonin reuptake inhibitors vs placeboSeverity of attacks · primary Raynaud's phenomenon1 finding from 1 reviewVasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 41 participantsVery low